Antiprogrammed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) monoclonal antibodies are immune checkpoint inhibitors (ICIs) that can improve survival in gastric and other cancers [16]. This evidence concerns the gene PDCD1 and cancer.